<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04594889</url>
  </required_header>
  <id_info>
    <org_study_id>NÂ° 1916-22/09/2020</org_study_id>
    <nct_id>NCT04594889</nct_id>
  </id_info>
  <brief_title>Comparison of Sirolimus vs Paclitaxel Drug Eluting Balloon for Below-the-knee Angioplasty in Critical Limb Ischemia</brief_title>
  <acronym>DebateBTKDuell</acronym>
  <official_title>Comparison of Sirolimus vs Paclitaxel Drug Eluting Balloon for Below-the-knee Angioplasty in Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale San Donato</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale San Donato</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the remote patency of paclitaxel versus sirolimus&#xD;
      eluting balloons in patients with CLI undergoing tibial artery revascularization. Patients&#xD;
      will be randomized 1:1 to Paclitaxel eluting balloon (Litos, ACOTEC ltd) or sirolimus eluting&#xD;
      balloon (Magic touch, Concept Medical) after optimal balloon angioplasty. The primary&#xD;
      endpoint of the study is the late luminal loss at 6 months angiography. Secondary endpoint&#xD;
      are major amputation, clinically driven target lesion revascularization and vessel&#xD;
      reocclusion (duplex) at 12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Critical ischemia of the limb is considered one of the most severe clinical scenario of&#xD;
      atherosclerotic disease involving the lower limb because it is associated with a high degree&#xD;
      of mortality and morbidity. Below the knee arterial disease is the basis of critical limb&#xD;
      ischemia (CLI). It is generally characterized by the involvement of multiple tibial arteries,&#xD;
      long lesions and high rate of hronic total occlusions. Percutaneous treatment of tibial&#xD;
      arteriopathy is characterized by high restenosis (70%). The advent of the drug-eluting&#xD;
      strategy has led to a reduction in the restenosis of the femoral and tibial district with&#xD;
      paclitaxel eluting devices. Data are not yet available on sirolimus eluting devices, both for&#xD;
      the femoropopliteal and tibial districts. The objective of this study is to compare the&#xD;
      remote patency of paclitaxel (Lithos) vs. the sirolimus (magic touch) eluting balloons in&#xD;
      patients with CLI undergoing tibial artery revascularization.&#xD;
&#xD;
      The study will enroll only patients with optimal balloon angioplasty defined by angiographic&#xD;
      and ultrasound criteria in order to avoid biases related to potentially unbalanced suboptimal&#xD;
      angioplasty results in both groups. The patients will be followed by either&#xD;
      interventionalists as well as diabetic foot specialists in order to optimize their&#xD;
      surveillance for lesion healings and vessel patency and reduced dropout.&#xD;
&#xD;
      Participating&#xD;
&#xD;
      Centers Cardiovascular disease department (San Donato Hospital, Arezzo, Italy) O.U.&#xD;
      Cardiology (San Iacopo Hospital, Pistoia, Italy) O.U. Cardiology (San Giuseppe Hospital,&#xD;
      Empoli, Italy) O.U Hemodynamics (A.O.U.C. Careggi, FlorenCe, Italy)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 14, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late Luminal Loss (LLL)</measure>
    <time_frame>6 months</time_frame>
    <description>LLL will be measured in the treated segment obtained subtracting the minimal lumen diameter at 6-month angiographic follow.up with minimal lumen diameter post intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major limb amputation</measure>
    <time_frame>12 months</time_frame>
    <description>amputation of target limb that requires a prostesis for standing and walking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven target lesion revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>repeat intervention of the target segment due to vessel restenosis documented by angiography and the presence of symptoms as follows:&#xD;
non healing ulcer&#xD;
rest pain of the treated limb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel occlusion (TVO)</measure>
    <time_frame>12 months</time_frame>
    <description>TVO will be documented by duplex ultrasond examination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <condition>Drug Effect</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sirolimus eluting balloon will be inflated in the target vessel after optimal balloon angioplasty for at least 2 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclkitaxel eluting balloon will be inflated in the target vessel after optimal balloon angioplasty for at least 2 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>angioplasty</intervention_name>
    <description>Balloon releasing a drug inflated in the target vessel</description>
    <arm_group_label>Paclitaxel</arm_group_label>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>PTA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18 and 85 years&#xD;
&#xD;
          2. CLI Rutherford class 4-6.&#xD;
&#xD;
          3. Stenosis or occlusion with length &gt;= 4 cm involving a tibial artery&#xD;
&#xD;
          4. Presence of angiographic distal runoff to the foot (stage 1-2a-2b of the Kawarada&#xD;
             classification)&#xD;
&#xD;
          5. Presence of optimal angioplasty result defined as residual stenosis &lt; 50%, absence of&#xD;
             flow limiting dissection, absence of vessel perforation, absence of distal&#xD;
             embolization by angiography and biphasic or triphasic flow at ultrasoud evaluation of&#xD;
             the target vessel&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy to one of the drugs in the study&#xD;
&#xD;
          2. Contraindications to antiplatelet therapy&#xD;
&#xD;
          3. Life expectancy less than 1 year&#xD;
&#xD;
          4. Major amputation planned before angiography&#xD;
&#xD;
          5. Inability to obtain informed consent -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Liistro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale San Donato</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Liistro, MD</last_name>
    <phone>+393381904695</phone>
    <email>francescoliistro@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paolo Angioli, MD</last_name>
    <phone>+390575255526</phone>
    <email>angiolipaolo@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale San Donato</name>
      <address>
        <city>Arezzo</city>
        <state>AR</state>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Liistro, MD</last_name>
      <phone>+393381904695</phone>
      <email>francescoliistro@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale San Donato</investigator_affiliation>
    <investigator_full_name>Francesco Liistro</investigator_full_name>
    <investigator_title>Cardiovascular Intervention Director</investigator_title>
  </responsible_party>
  <keyword>CLI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

